SI2379100T1 - Zdravljenje hiperglikemije z GLP-1 - Google Patents

Zdravljenje hiperglikemije z GLP-1

Info

Publication number
SI2379100T1
SI2379100T1 SI201030852T SI201030852T SI2379100T1 SI 2379100 T1 SI2379100 T1 SI 2379100T1 SI 201030852 T SI201030852 T SI 201030852T SI 201030852 T SI201030852 T SI 201030852T SI 2379100 T1 SI2379100 T1 SI 2379100T1
Authority
SI
Slovenia
Prior art keywords
glp
treating hyperglycemia
hyperglycemia
treating
Prior art date
Application number
SI201030852T
Other languages
English (en)
Inventor
Donald Costello
Peter Richardson
Robert A. Baughman
Mark T. Marino
Original Assignee
Mannkind Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corporation filed Critical Mannkind Corporation
Publication of SI2379100T1 publication Critical patent/SI2379100T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201030852T 2009-01-08 2010-01-08 Zdravljenje hiperglikemije z GLP-1 SI2379100T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14335809P 2009-01-08 2009-01-08
EP10700456.6A EP2379100B1 (en) 2009-01-08 2010-01-08 Treating hyperglycemia with glp-1
PCT/US2010/020448 WO2010080964A1 (en) 2009-01-08 2010-01-08 Method for treating hyperglycemia with glp-1

Publications (1)

Publication Number Publication Date
SI2379100T1 true SI2379100T1 (sl) 2015-02-27

Family

ID=41820660

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030852T SI2379100T1 (sl) 2009-01-08 2010-01-08 Zdravljenje hiperglikemije z GLP-1

Country Status (12)

Country Link
US (1) US9078866B2 (sl)
EP (2) EP2379100B1 (sl)
JP (2) JP5918539B2 (sl)
AU (2) AU2010203573A1 (sl)
CA (1) CA2749099A1 (sl)
DK (1) DK2379100T3 (sl)
ES (1) ES2529100T3 (sl)
HK (1) HK1164112A1 (sl)
MX (1) MX2011007371A (sl)
PT (1) PT2379100E (sl)
SI (1) SI2379100T1 (sl)
WO (1) WO2010080964A1 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280021B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
US7820676B2 (en) 2004-08-23 2010-10-26 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
CA2621806C (en) 2005-09-14 2016-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20210027546A (ko) 2009-06-12 2021-03-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
CN104755097A (zh) * 2012-08-29 2015-07-01 曼金德公司 用于治疗高血糖症的方法和组合物
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
DE202016104106U1 (de) 2015-08-07 2016-10-09 Hitachi Koki Co., Ltd. Elektrowerkzeug

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
KR20010073033A (ko) 1998-08-28 2001-07-31 피터 지. 스트링거 인슐리노트로픽 펩티드의 투여 방법
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280021B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
AU2001232735A1 (en) 2000-01-27 2001-08-07 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 compounds
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
EP1301187B1 (en) * 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040121964A1 (en) 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure
CA2552707C (en) * 2004-01-12 2018-03-27 Mannkind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
US20050265927A1 (en) 2004-05-17 2005-12-01 Yale University Intranasal delivery of nucleic acid molecules
US7820676B2 (en) 2004-08-23 2010-10-26 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
CA2589118A1 (en) 2004-12-03 2006-06-08 Mederio Ag A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
SE0402976L (sv) 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
MX2007008379A (es) * 2005-01-10 2008-02-19 Mannkind Corp Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
BRPI0614489A2 (pt) * 2005-08-01 2011-03-29 Mannkind Corp método para preservar a função de células produtoras de insulina
CA2621806C (en) 2005-09-14 2016-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
KR101438839B1 (ko) 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
JP2011500850A (ja) * 2007-10-24 2011-01-06 マンカインド コーポレイション Ｇｌｐ−１による副作用を防止する方法
JP5813323B2 (ja) * 2007-10-24 2015-11-17 マンカインド コーポレイション 活性薬剤の送達方法

Also Published As

Publication number Publication date
ES2529100T3 (es) 2015-02-16
EP2853268A1 (en) 2015-04-01
HK1164112A1 (en) 2012-09-21
US20120094905A1 (en) 2012-04-19
WO2010080964A1 (en) 2010-07-15
AU2010203573A1 (en) 2011-06-30
DK2379100T3 (en) 2014-12-01
EP2379100A1 (en) 2011-10-26
US9078866B2 (en) 2015-07-14
PT2379100E (pt) 2015-02-09
JP2012514646A (ja) 2012-06-28
EP2379100B1 (en) 2014-11-12
JP2015157817A (ja) 2015-09-03
MX2011007371A (es) 2011-09-06
JP5918539B2 (ja) 2016-05-18
AU2016200249A1 (en) 2016-02-04
CA2749099A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
HK1164112A1 (en) Treating hyperglycemia with glp-1 glp-1
ZA201204436B (en) Double-acylated glp-1 derivatives
HK1161275A1 (en) Halogen-stabilized insulin
GB2469672B (en) Improved autoinjector
PL2490735T3 (pl) Automatyczny wstrzykiwacz
ZA201100056B (en) Syringe with disabling mechanism
GB201001672D0 (en) Improved autoinjector
GB0913385D0 (en) Improved autoinjector
GB0913136D0 (en) Auto-injector
EP2464219A4 (en) MULTI-TRANSGENIC PIGS FOR DIABETES TREATMENT
IL207583A0 (en) Treating hyperglycemia with 25-hydroxyvitamin d3
GB0910681D0 (en) Auto-injector
AP3315A (en) Detoxification with reducing agents
GB0900599D0 (en) Treatment
GB0812019D0 (en) Insulin
GB201013898D0 (en) Well treatment
EG26793A (en) Medical Injector
GB201114309D0 (en) Document treatment icon
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
GB2472645B (en) Latch arrangement
GB201001393D0 (en) Latch
EP2384338A4 (en) GLP-1 ANALOGS AND THEIR APPLICATIONS
GB0808387D0 (en) Glp-1
GB2475272B (en) Latch arrangement